Implications of Chromosome 4 Open Reading Frame 29 (ABHD18) in Disease Development

Target Name: ABHD18

NCBI ID: G80167

ABHD18

Implications of Chromosome 4 Open Reading Frame 29 (ABHD18) in Disease Development

Chromosome 4 open reading frame 29 (ABHD18) is a gene that encodes a protein known as alpha-beta-hydroxy-methylbutyrate (浼?-灏?-HMB) dehydrogenase (浼?-灏?-HMBD). This gene is located on chromosome 4 and has has been implicated in a number of cellular processes, including metabolism, cell signaling, and inflammation.

浼?-灏?-HMBD is a non-protein protein that is synthesized from the amino acids Asp222, Asn223, Glu224, Lys225, Asp226, and Asn227. It is expressed in a variety of tissues, including brain, heart, skeletal muscles , and tissues. The primary function of 浼?-灏?-HMBD is to convert nicotinamide (vitamin B3) to nicotinamide N-oxide (NMN), a molecule that is involved in a number of cellular processes, including metabolism, cell signaling, and DNA repair.

In recent years, the study of 浼?-灏?-HMBD has gained significant interest as a potential drug target and biomarker. The 浼?-灏?-HMBD gene has been shown to be involved in a number of diseases, including cancer, neurodegenerative diseases, and metabolic disorders. Additionally, the 浼?-灏?-HMBD gene has been shown to be involved in a number of cellular processes that are associated with aging, such as muscle wasting, cognitive decline, and increased risk of certain diseases.

Drug Targets

浼?-灏?-HMBD has been identified as a potential drug target due to its involvement in a number of cellular processes that are associated with the aging process. For example, studies have shown that 浼?-灏?-HMBD is involved in the production of NMN , which is a molecule that is involved in a number of cellular processes that are associated with aging, such as muscle wasting, cognitive decline, and increased risk of certain diseases.

In addition, 浼?-灏?-HMBD has also been shown to be involved in the production of reactive oxygen species (ROS), which are molecules that can damage cellular components and contribute to the aging process. ROS are generated by a variety of cellular processes, including metabolism and cellular signaling, and can cause a number of cellular problems, including the development of certain diseases.

Biomarkers

浼?-灏?-HMBD has also been identified as a potential biomarker for a number of diseases, including cancer, neurodegenerative diseases, and metabolic disorders. For example, studies have shown that 浼?-灏?-HMBD is often reduced in certain types of cancer, and that it is involved in the development of certain neurodegenerative diseases. Additionally, 浼?-灏?-HMBD has also been shown to be involved in the development of certain metabolic disorders, such as type 2 diabetes.

Conclusion

浼?-灏?-HMBD is a gene that encodes a protein that is involved in a number of cellular processes, including metabolism, cell signaling, and inflammation. It is also involved in the production of NMN and ROS, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and metabolic disorders. As a result, 浼?-灏?-HMBD is a potential drug target and biomarker for a number of diseases. Further research is needed to fully understand the role of 浼?-灏?-HMBD in cellular processes and its potential as a drug.

Protein Name: Abhydrolase Domain Containing 18

The "ABHD18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABHD18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets